About Us

Our mission is to redefine the way the brain is measured and treated to optimise patient outcomes across the care continuum.

CoMind is a team of highly skilled and passionate individuals working towards the development of innovative neuromonitoring devices and neural interfaces.

Through the technology we are building, doctors will gain access to a huge range of critical neurophysiological signals, many of which are inaccessible today, in a single, simple, non-invasive measurement at the patient’s bedside.

The Team

Leading experts with a proven track record of developing and commercialising products globally.

James Dacombe Founder, Chief Executive Officer and Chairman

James founded CoMind at the age of seventeen, having already developed a strong understanding of software engineering. James was named on the 2022 Forbes 30 under 30 Technology list and awarded a Thiel Fellowship. The Fellowship empowers individuals under 23 years old who have distinguished themselves in business, science or social causes.

Dr. Rob Cooper Chief Scientific Officer

Rob is a Medical Physicist and research leader specialising in optical imaging and sensing of the human brain. Rob is an Associate Professor of Biomedical Optics at University College London, has more than 15 years experience developing and applying non-invasive brain sensing technologies, and has published more than 80 peer-reviewed papers, articles, abstracts and book chapters. Rob has a track record of working at the intersection of research, neuroscience, medicine and commercial device development.

Chema Garcia-Soto, MBA Chief Commercial Officer

Chema is an entrepreneurial business professional with extensive multi-functional experience in finance, operations, customer service, sales and marketing in the logistics and medical technology industries. He served 11 years at the global medtech leader Medtronic, where he had a successful record building businesses from the ground up. Chema brings a strong global network of clients, distributors, GPOs, and medical device industry talent, as well as a robust network of investors. During his career he developed a diverse and multicultural experience performing in a variety of leadership positions in Europe, Middle East, U.S.A. and Latin America. Chema has acquired a strong business acumen at the world’s top business schools; IESE, UCLA, MIT, Stanford and European Business School.

Dr. Marc Bloom Chief Medical Officer

Dr. Marc Bloom is professor of anesthesiology and former Chief Neuroanesthesiologist at the University of Miami. Prior to that, he served as Director of perioperative technology and co-director of the neuroanesthesia division at NYU Langone medical centre. Dr. Bloom is an MD and PhD in biomedical engineering from the University of Pennsylvania. An expert in the field, both from the medical and the engineering disciplines, he has advised companies such as Aspect Medical, Covidien, Masimo, Stryker and Epic in the development of new products. Dr. Bloom brings his wealth of knowledge and his more than 40 years as a member of the American Society of Anesthesiology and past president of the American Society of Neurophysiological Monitoring, to develop the next generation of neurotechnologies with CoMind.

Dr. Claus Lindner Director of Engineering

Claus has over 5 years of industry experience and has taken several medical devices through regulatory approval. Claus is a Physicist and holds a PhD in Medical Optics (TD-NIRS & DCS in the clinic) from the Institute of Photonic Sciences. Claus’ work is focused on the intersection between physics, computer science, signal processing, biology, medicine and engineering on an international scale for the development of novel artificial intelligence, computer vision, machine and deep learning applications and advanced analytics solutions. His works translate physics concepts for the improvement of patient care. Claus opened a new research area for diffused optics and its application to cancer screening.

Morgan Lockyer Chief of Staff

Morgan has amassed over 9 years of operational experience and has been an early adopter of successful startups. She has made a career of helping start-ups scale, supporting two acquisitions and delivering a measured impact on businesses whilst gaining invaluable knowledge and experience. Morgan has in depth experience leading customer teams, overseeing technical implementation projects, managing vendor relationships and establishing business best practice.

Mimosa Nguyen Director of People

Mo has over 12 years of people and operations experience from the likes of Google, Lyft, and Woven by Toyota. With a passion for early stage start ups, Mo has supported and grown teams over three continents and through multiple acquisitions. Mo works to build culture by aligning People strategies with the needs of the business, creating infrastructure, and empowering employees to operate at their highest potential.

Dr. Dawid Borycki Staff Research Scientist

Dawid is a world-leader in the design and development of biomedical optical technologies and particularly in interferometric methods for noninvasive, ultrafast human tissue imaging and sensing. His expertise includes software development, signal and image processing, biomedical optics theory, device control, numerical simulations, experiment planning and implementation. Dawid is an Assistant Professor at Nicolaus Copernicus University, Poland, but has spent most of the last few years focussed on translating his successful academic research into impactful commercial applications. At CoMind, Dawid leads the Experimental Optics team, exploring new concepts and driving technologies through the early stages of product development.

Scientific Advisory Board

World-leading academics and clinicians. The board is charged with providing independent, broad-scope scientific and clinical guidance for the research, development, and clinical translation work being undertaken at CoMind.

Professor Philip Bath Scientific Advisory Board Member

Philip is Stroke Association Professor of Stroke Medicine at the University of Nottingham, where he is also Head of Academic Stroke. Philip has decades of expertise at the forefront of the treatment and investigation of stroke and vascular neurology. He has also established and led numerous small, medium and large-scale clinical trials targeted at the treatment and prevention of stroke.

Dr. Mark Chevillet Chair of the Scientific Advisory Board

Mark has an extraordinary track record working at the cutting edge of neurotechnology development across multiple sectors. He is the former Director of Research at Facebook’s BCI Program and an Adjunct Professor in the Department of Neuroscience at John’s Hopkins University. Mark holds a PhD in Neuroscience and provides CoMind with deep commercial, technological, and neuroscientific insight.

Professor Turgut Durduran Scientific Advisory Board Member

Turgut is the head of the world-leading Medical Optics group at the Institute of Photonic Sciences (ICFO), Spain, and holds a prestigious ICREA Professorship. Turgut founded the Medical Optics group in 2009 and is a leading voice in the development of coherent optical sensing methods. He has authored over one hundred peer-reviewed papers, led numerous high-profile multi-million dollar research projects, and has delivered numerous invited talks in international conferences and colloquia.

Dr. Jana Kainerstorfer Scientific Advisory Board Member

Jana is an Associate Professor of Biomedical Engineering at Carnegie Mellon University. Jana’s extensive research has a focus on developing non-invasive optical imaging methods for disease detection and monitoring, with a particular emphasis on neuromonitoring and neurophysiology.

Dr. David Segar Scientific Advisory Board Member

David is chief neurosurgical resident at Harvard Medical School, Brigham and Women’s and Boston Children’s Hospitals. He has served as a visiting scientist at institutions including MIT, Brown University, and the Wyss Center for Bio and Neuroengineering in Geneva, where his research focuses on invasive human neurophysiology and the development of novel forms of neuromodulation. David has developed particular expertise in medical device development, with experience spanning from invention to clinical translation, and serves in both executive and advisory roles to several clinical neurotechnology ventures.

Careers

Help us advance neurosensing for brain disorder patients globally

Learn more